Loading
Vorolanib is Betta Pharmaceuticals' oral VEGFR and PDGFR inhibitor, approved in China in 2023 with everolimus for advanced kidney cancer after a first kinase inhibitor has failed.
Vorolanib (X-82, CM082) was developed by Betta Pharmaceuticals in Hangzhou, licensed from Tyrogenex. The NMPA approved it in June 2023 in combination with everolimus for advanced renal cell carcinoma in patients whose disease had progressed on a prior tyrosine kinase inhibitor, on the CONCEPT phase 3 trial, which compared the combination with everolimus alone. It is also in trials in lung cancer and, as an eye drop formulation, in retinal disease.
Blocks the VEGF and PDGF receptors that build and stabilise tumour blood vessels; designed as a shorter-acting relative of sunitinib to limit off-target toxicity. Connects to VEGF / VEGFR.
1.Vorolanib slips into a pocket on VEGF / VEGFR.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| CN | 2023 | Advanced renal cell carcinoma after a prior tyrosine kinase inhibitor, with everolimus (June 2023) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Vorolanib" OR ABSTRACT:"Vorolanib" OR TITLE:"X-82" OR ABSTRACT:"X-82" OR TITLE:"CM082" OR ABSTRACT:"CM082" OR TITLE:"Fuwei" OR ABSTRACT:"Fuwei") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Vorolanib, not a curated reading list.
Shares VEGF / VEGFR, Small-molecule kinase inhibitors and the tags china, nmpa-approved.
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.